1. The American Cancer Society-Cancer Facts and Figures, 2007.
http://www.cancer.org
. Accessed June 15, 2007.
2. Trope CG, Alektiar KM, Sabbatini PJ, et al.: Corpus: epithelial tumors. In Principles and Practice of Gynecologic Oncology, edn 4. Edited by Hoskins WP, Perez CA, Young RC, et al. Philadelphia: Lippincott Williams & Wilkins; 2005:823–872.
3. Cohen CJ, Bruckner NW, Deppe G, et al.: Multidrug treatment of advanced and recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Obstet Gynecol 1984, 63:719–726.
4. Thigpen JT, Blessing JA, DiSaia PJ, et al.: A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 1994, 12:1408–1414.
5. Thigpen JT, Blessing JA, DiSaia PJ, et al.: A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2004, 22:3902–3908.